Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.31 USD
Change Today +0.17 / 4.11%
Volume 152.9K
ABEO On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

abeona therapeutics inc (ABEO) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/4/14 - $15.00
52 Week Low
04/30/15 - $2.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

abeona therapeutics inc (ABEO) Related Businessweek News

No Related Businessweek News Found

abeona therapeutics inc (ABEO) Details

Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Its lead programs are AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers, and clinicians. The company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including SDF AlphaT (alpha-1 protease inhibitor) for inherited COPD using its proprietary Salt Diafiltration (SDFT) ethanol-free process. The company is involved in marketing MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

7 Employees
Last Reported Date: 03/31/15
Founded in 1989

abeona therapeutics inc (ABEO) Top Compensated Officers

Executive Chairman
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: $97.0K
Chief Operating Officer and Director
Total Annual Compensation: $290.0K
Senior Vice President of Research & Developme...
Total Annual Compensation: $129.0K
Compensation as of Fiscal Year 2014.

abeona therapeutics inc (ABEO) Key Developments

Abeona Therapeutics Inc., Q2 2015 Earnings Call, Aug 20, 2015

Abeona Therapeutics Inc., Q2 2015 Earnings Call, Aug 20, 2015

Abeona Eyes Acquisitions

Abeona Therapeutics Inc. (NasdaqCM:ABEO) is looking for acquisition opportunities. Abeona offering directly to investors 2.829 million shares of our common stock. Additionally Abeona offering 20,000 shares of Abeona common stock underlying a warrant issued by us to a previous placement agent. The net proceeds from the sale of the securities to which this prospectus supplement relates will be used for general corporate purposes. General corporate purposes may include repayment of debt, acquisitions, additions to working capital, capital expenditures, research and development, and investments in our subsidiaries. Net proceeds may be temporarily invested prior to use.

Abeona Therapeutics Inc. Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-10-2015 09:35 AM

Abeona Therapeutics Inc. Presents at Rodman & Renshaw 17th Annual Global Investment Conference, Sep-10-2015 09:35 AM. Venue: The St. Regis Hotel, Two East 55th Street, New York, NY 10022, United States. Speakers: Timothy J. Miller, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABEO:US $4.31 USD +0.17

ABEO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $33.55 USD +0.82
DARA BioSciences Inc $0.86 USD +0.016
Grifols SA €37.28 EUR +0.24
Harmonic Drive Systems Inc ¥1,780 JPY +44.00
View Industry Companies

Industry Analysis


Industry Average

Valuation ABEO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 109.7x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 109.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABEONA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at